基于成纤维细胞活化蛋白抑制剂的放射性核素治疗:现状与未来方向
本文综述了临床前和临床阶段基于成纤维细胞活化蛋白(FAP)抑制剂的放射性核素治疗研究,描述了该新型疗法的进展、FAP分子修饰、剂量测定、安全性特征与疗效,并指出该总结可能指导未来研究方向并优化这一新兴领域的临床决策。
要点
- 癌相关成纤维细胞与肿瘤及免疫细胞复杂互动,参与肿瘤生长、侵袭、转移和治疗抵抗。
- 基于FAP抑制剂的分子影像在癌症诊断中显示令人鼓舞的结果,使其成为放射性核素治疗的创新靶点。
- 本综述总结了基于FAP的放射性核素治疗的临床前和临床结果,涵盖进展、分子修饰、剂量测定、安全性与疗效。
核心结论
- 本综述总结可能指导未来研究方向并优化这一新兴领域的临床决策。
研究设计与样本
- 本综述总结了基于FAP抑制剂的放射性核素治疗的临床前和临床研究结果。
主要发现
- 促癌癌相关成纤维细胞成为有吸引力的治疗靶点,但临床试验已取得的成功欠佳。
- 基于FAP抑制剂的分子影像在癌症诊断中显示令人鼓舞的结果,使其成为基于FAP抑制剂放射性核素治疗的创新靶点。
- 本综述描述了该新型疗法的进展与FAP分子修饰,以及其剂量测定、安全性特征与疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metastatic malignancies have limited management strategies and variable treatment responses. Cancer cells develop beside and depend on the complex tumor microenvironment. Cancer-associated fibroblasts, with their complex interaction with tumor and immune cells, are involved in various steps of tumorigenesis, such as growth, invasion, metastasis, and treatment resistance. Prooncogenic cancer-associated fibroblasts emerged as attractive therapeutic targets. However, clinical trials have achieved suboptimal success. Fibroblast activation protein (FAP) inhibitor-based molecular imaging has shown encouraging results in cancer diagnosis, making them innovative targets for FAP inhibitor-based radionuclide therapies. This review summarizes the results of preclinical and clinical FAP-based radionuclide therapies. We will describe advances and FAP molecule modification in this novel therapy, as well as its dosimetry, safety profile, and efficacy. This summary may guide future research directions and optimize clinical decision-making in this emerging field.
引用
- Ora M, Soni N, Nazar AH, et al. Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions. J Nucl Med. 2023. PMID: 37268422. doi:10.2967/jnumed.123.265594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。